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Abstract
Survivin is a microtubule-associated protein believed to be involved in preserv-
ing cell viability and regulating tumor cell mitosis, and it is overexpressed in
many primary tumor types, including melanoma. YM155 is a first-in-class sur-
vivin suppressant. The purpose of this Phase 2 study was to evaluate the
6-month progression-free survival (PFS) rate in patients with unresectable
Stage III or IV melanoma receiving a combination of YM155 plus docetaxel.
The study had two parts: Part 1 established the dose of docetaxel that was toler-
able in combination with YM155, and Part 2 evaluated the tolerable docetaxel
dose (75 mg/m2) in combination with YM155 (5 mg/m2 per day continuous
infusion over 168 h every 3 weeks). The primary endpoint was 6-month PFS
rate. Secondary endpoints were objective response rate (ORR), 1-year overall
survival (OS) rate, time from first response to progression, clinical benefit rate
(CBR), and safety. Sixty-four patients with metastatic melanoma were treated
with docetaxel and YM155. Eight patients received an initial docetaxel dose of
100 mg/m2 and 56 patients received 75 mg/m2 of docetaxel. Six-month PFS
rate per Independent Review Committee (IRC) was 34.8% (n = 64; 95% CI,
21.3–48.6%), and per Investigator was 31.3% (n = 64; 95% CI, 19.5–43.9%).
The best ORR (complete response [CR] + partial response [PR]) per IRC was
12.5% (8/64). The stable disease (SD) rate was 51.6% (33/64), leading to a CBR
(CR + PR + SD) of 64.1% (41/64). Estimated probability of 1-year survival was
56.3%. YM155 is a novel agent showing modest activity when combined with
docetaxel for treating patients with melanoma. YM155 was generally well toler-
ated, but the predetermined primary efficacy endpoint (i.e., 6-month PFS rate
≥20%) was not achieved.
Introduction
Melanoma is a major health problem, with a rapidly ris-
ing incidence and mortality. Until 2011, dacarbazine and
high-dose interleukin-2 were the only drugs approved for
this disease; however, neither of these agents has been
shown to improve median overall survival (OS) [1, 2].
The therapeutic landscape for this disease has changed in
recent years, with the introduction of targeted and
immune therapies, such as ipilimumab, pembrolizumab,
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vemurafenib, dabrafenib, and trametinib. These therapies
recently received US Food and Drug Administration
approval based on OS benefit (of note, these approvals
came after the completion of the current study).
Other targeted agents are being investigated because they
interfere with cell growth control and promote tumor cell
death. For instance, drug candidates which are survivin sup-
pressants are being evaluated for potential antitumor activity,
such as the first-in-class small molecule YM155 [3]. Survivin
is a member of the inhibitor of apoptosis protein family, and
has been implicated in both cell survival and regulation of
mitosis in cancer [4]. Overexpression of survivin has been
observed in many primary tumor types, including mela-
noma, and its expression in sentinel lymph nodes has been
associated with patient outcome [5]. Survivin suppression by
small interfering RNA-induced spontaneous apoptosis in
melanoma cells [3]. These facts suggest that survivinmay be a
target for the treatment of melanoma (i.e., by using survivin
suppressant YM155). Preclinical studies showed that YM155
suppressed both survivin protein and mRNA expression [6].
Furthermore, in human studies, monotherapy with YM155
has shownmodest clinical activity with a tolerable safety pro-
file in phase 1 and 2 trials inmultiple cancer types [7–10].
Survivin has been implicated in the regulation of sponta-
neous apoptosis rates in melanoma cells [3], and survivin
suppression increases sensitivity to existing chemotherapeu-
tic drugs and apoptotic stimuli [4, 11, 12]. Thus, combining
YM155 with a known chemotherapeutic agent may have a
synergistic effect. Docetaxel is a chemotherapeutic agent
that prevents mitotic spindle breakdown by stabilizing
microtubule bundles. Docetaxel monotherapy has shown a
low response rate (6%–17%) in patients with melanoma
[13–15], and long-term treatment with docetaxel is limited
because of drug resistance and side effects. In a human mel-
anoma model, YM155 enhanced docetaxel’s antitumor
activity, without increasing body weight loss, suggesting
that the combination of YM155 with docetaxel may be
effective for the treatment of melanoma [3].
The purpose of this Phase 2 study was to evaluate the
6-month progression-free survival (PFS) rate among
patients with unresectable Stage III or IV melanoma who
received YM155 plus docetaxel based upon historical con-
trols [16]. This combination of treatments for melanoma
was developed at a time when other effective therapies
were not available; thus, at the time of its development,
YM155 was a first-in-classtargeted therapy.
Materials and Methods
Study design
This study was an open-label, nonrandomized multicenter
study (NCT01009775) supported by Astellas Pharma
Global Development. The study consisted of two parts.
Part 1 established the dose of docetaxel that was tolerable
in combination with YM155 at 5 mg/m2 per day continu-
ous infusion over 168 h every 3 weeks. Part 2 used the
established docetaxel dose (75 mg/m2) from Part 1 to fur-
ther evaluate the tolerability and activity of the combina-
tion. The primary endpoint was 6-month PFS rate.
Secondary endpoints were objective response rate (ORR),
1-year OS rate, time from first response to progression,
clinical benefit rate (CBR), time to response, and safety.
The protocol was approved by the appropriate institu-
tional review boards and was conducted in accordance
with the ethical principles originating from the Declara-
tion of Helsinki and with Good Clinical Practice, as
defined by the International Conference on Harmoniza-
tion. All patients provided written informed consent
before enrollment.
Inclusion and exclusion criteria
Patient inclusion criteria were age ≥18 years; histologically
confirmed unresectable Stage III or IV melanoma; Eastern
Cooperative Oncology Group (ECOG) performance status
0 or 1; no prior systemic treatment for advanced mela-
noma except for adjuvant treatment; measureable disease
per Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST v1.1); and life-expectancy >12 weeks. Exclu-
sion criteria included: presence or history of brain metas-
tases, primary ocular melanoma, or mucosal melanoma;
baseline neuropathy >Grade 2; and serum creatinine
>1.5 times the upper limit of normal (ULN). Adequate
liver and bone marrow function were also required prior
to enrollment. Patients with a positive test for Hepatitis B
surface antigen or Hepatitis C antibody, or with a history
of a positive test for human immunodeficiency virus were
excluded.
Drug administration
One treatment cycle was defined as 21 days, divided into
a 7-day treatment period followed by a 14-day observa-
tion period (Figure 1). During Part 1, the starting dose of
docetaxel was 100 mg/m2, administered intravenously
over 1 h, but could be reduced to 75 mg/m2 for antici-
pated toxicity such as neuropathy or leukopenia; this dos-
ing regimen was established in a previous Phase 2 trial
[15]. Docetaxel was administered on Day 1 of every 21-
day cycle, using standard of care procedures including
premedication with corticosteroids. Part 2 used the estab-
lished docetaxel dose (75 mg/m2) from Part 1 (based on
dose-limiting toxicities [DLTs]), to further evaluate the
tolerability and activity of combination therapy with
YM155 and docetaxel. YM155 was provided in vials, as
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an aqueous solution that was further diluted for adminis-
tration with an appropriate volume of concentrated stock
solution in 5% dextrose in water or 0.9% normal saline
in a light- and temperature-controlled environment. The
drug was administered at a dose of 5 mg/m2 per day by
continuous intravenous infusion over 168 h via a portable
electronic infusion pump through a central line, port, or
peripherally inserted central catheter line. YM155 was
administered within 1 h of completing docetaxel infusion
on Day 1 of each cycle. Patients could receive the study
regimen until experiencing unacceptable toxicity or dis-
ease progression, or until withdrawal of consent. Patients
experiencing intolerable docetaxel toxicity were allowed to
continue treatment with YM155 alone.
Tolerability and safety evaluations
The following safety assessments were collected for each
patient: subjective and objective symptoms, vital signs,
laboratory tests, and 12-lead electrocardiogram. Adverse
events (AEs) were graded according to the National Can-
cer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE), version 4.02. DLT was assessed
for patients in Part 1 of the study. A DLT was defined as
any study drug-related NCI CTCAE Grade 4 hematologi-
cal or Grade 2 nonhematological (excluding temporary
hyperglycemia, alopecia, fatigue, and anorexia) toxicity.
Specific modifications to the NCI CTCAE toxicities that
are considered DLTs included the following: ANC <500/
mm3 for >5 days; platelet count <25,000/mm3; serum
creatinine >three times the ULN; ≥Grade 2 nausea, vom-
iting, or diarrhea in the presence of maximal prophylaxis;
any Grade 4 liver toxicity or upward change in liver
function studies of two grades for patients with preexist-
ing liver function elevation; and/or treatment delay of
>14 days.
Pharmacokinetics and exploratory
assessments
Blood samples were collected on Day 4 (1 day), Day 8
before discontinuation of YM155, and Day 8 within
30 min to 4 h after discontinuation of YM155 during
cycles 1–3 to measure plasma concentrations of YM155
and its metabolites. The samples were collected in vac-
uum tubes containing sodium heparin, kept chilled under
ice with light protection, and centrifuged within 30 min
of collection. Plasma YM155 and metabolite concentra-
tions were measured at a bioanalytical laboratory (Phar-
maceutical Product Development [PPD], Richmond, VA)
using validated liquid chromatography–mass spectrometry
methods. The analytes were isolated from a 0.1 mL
plasma volume using solid phase extraction and quanti-
fied over an assay range of 0.05–25 ng/mL.
Exploratory endpoints included pharmacodynamic
evaluation of potential biomarkers. Biomarker assessments
were performed on unstained tumor tissue slides from
either a historical biopsy or new biopsy for immunohisto-
chemical (IHC) staining. IHC staining was performed, if
sufficient tumor was available, to obtain information on
the correlation between clinical outcome and the preva-
lence of resistance markers (e.g., p–glycoprotein-1, OCT–
1, OCT–2) and mechanistic markers (e.g., survivin, PARP
cleavage product p85, phosphorylated Erk1/2). If the
amount of sample was limited, analyses were prioritized
based upon significance in nonclinical studies.
Blood samples were collected before and after both
docetaxel and YM155 infusions to evaluate for tumor apop-
tosis by M30 Apoptosense enzyme-linked immunosorbent
assay (ELISA), a plasma-based test measuring a soluble
cleavage product of tumor apoptosis, by means of creat-
ing a neoepitope of cytokeratin 18 (tumor-specific), dur-
ing apoptotic cleavage. A Student’s t-test analysis was
Figure 1. Study flow diagram.
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 645
R. Kudchadkar et al. YM155 Plus Docetaxel in Metastatic Melanoma
performed on longitudinal serum samples to correlate
M30 change from baseline with clinical response.
Tumor assessments
Efficacy assessments were determined through results
from radiological imaging and objective tumor assess-
ments according to the requirements of RECIST v1.1.
Imaging studies (i.e., diagnostic CT or MRI scans) were
performed at baseline and every 6 weeks throughout the
study.
Statistical analysis
The 6-month PFS rate was defined as the probability that
a patient survives without objective tumor progression at
6 months (24 weeks) after the first dose of the study regi-
men. Tumor progression was assessed by independent
radiological review. A predetermined primary endpoint
benchmark (i.e., 6-month PFS rate ≥20%) for efficacy was
established, below which the combination treatment was
deemed not worthy of further investigation [16]. The fol-
lowing patients were censored at the date of the last ade-
quate radiological assessment: patients who initiated
another systemic treatment for melanoma, patients who
progressed or died after missing ≥2 consecutive radiologi-
cal assessments, and patients who died >89 days after last
tumor scan. The full analysis set (FAS; defined as all
patients who initiated ≥1 dose of YM155) was used for
primary efficacy analyses. A sample size of 60 patients for
Part 2 of the study was required to have 94% power to
test the null hypothesis of 6-month PFS rate of 20%,
using a one-sided alpha of 0.025. The 6-month PFS rate
with the corresponding two-sided 95% confidence inter-
vals (CIs) for the FAS were calculated using Kaplan–Me-
ier estimates. The study was considered successful only if
the lower boundary of the 95% CI for 6-month PFS was
>20%.
Other endpoints included ORR, PFS, OS, 1-year sur-
vival rate, duration of response, CBR, and safety.
Results
Patients
Sixty-four patients were enrolled from December 2009 to
September 2010 (Part 1, n = 3; Part 2, n = 61). During
cycle 1 of Part 1, three patients received 100 mg/m2 of
docetaxel, and experienced DLTs (e.g., reduced neutrophil
count, neutropenia, febrile neutropenia) indicating the
dose was not well tolerated. Per protocol instructions, a
reduced dose of 75 mg/m2 was to be initiated for the
61 patients in Part 2, although five patients in Part 2
actually received starting doses of 100 mg/m2, constitut-
ing protocol violations. All protocol violations were
reported to the IRB per institutional guidelines. Of the 64
patients in both parts of the study, 25 (39.1%) had their
docetaxel dose reduced; all eight patients initially receiv-
ing 100 mg/m2 were reduced to 75 mg/m2, 16 patients
were reduced from 75 mg/m2 to 55 mg/m2, and one
patient was reduced from 75 mg/m2 to 60 mg/m2. All
patients initiated YM155 at 5 mg/m2 per day continuous
infusion over 168 h every 3 weeks along with docetaxel;
seven patients received YM155 dose reductions to 3.6 mg/
m2 per day. All enrolled patients (n = 64) were included
in the FAS, per-protocol set, pharmacokinetics set, and
safety analysis set; thus, all analyses include all enrolled
patients, unless otherwise specified.
The demographic and baseline patient characteristics
are listed in Table 1. The population consisted of a poor
prognostic group with 73.4% of the patients with M1c
disease. The median (range) age was 59 (26–79) years.
Safety
A list of all common (i.e., occurring in ≥10% of patients)
AEs appears in Table 2. The majority of AEs were judged
by treating investigators to be Grade 1 or 2 severity, with
the most common low-grade AE being fatigue (78.1%).
The most clinically significant Grade 3 or 4 toxicities
occurring in >5% of patients treated included neutropenia
Table 1. Baseline patient characteristics.
Characteristic Patients (n = 64)
Sex, n (%)
Male 44 (68.8)
Female 20 (31.3)
Ethnicity, n (%)
Not Hispanic or Latino 63 (98.4)
Hispanic or Latino 1 (1.6)
Age
Median (range), years 59 (26–79)
<65 years, n (%) 37 (57.8)
≥65 years, n (%) 27 (42.2)
ECOG performance status, n (%)
Grade 0 41 (64.1)
Grade 1 23 (35.9)
Metastatic (M) classification at diagnosis, n (%)
M1a and M1b 17 (26.6)
M1c 47 (73.4)
Serum LDH, n (%)
No data 1 (1.6)
Normal 6 (9.4)
Elevated 57 (89.1)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydroge-
nase.
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(59.4%), leukopenia (28.1%), decreased neutrophil count
(25.0%), febrile neutropenia (17.2%), white blood cell
count decrease (15.6%), mucositis (9.4%), fatigue (7.8%),
diarrhea (6.3%), and dehydration (6.3%). Most patients
(90.6%) experienced Grade 3 or 4 toxicities that were
attributed to either YM155 or docetaxel. Three deaths
occurred during the study; all were attributable to disease
progression by the investigator.
Pharmacokinetic analysis
The median (range) plasma concentrations of YM155 on
Day 4 during the first, second, and third infusions of
YM155 were 6.510 (3.01–209.93) ng/mL, 6.070 (2.01–
14.99) ng/mL, and 6.390 (3.13–489.06) ng/mL, respec-
tively. Median YM155 concentrations in samples collected
before the end of YM155 infusion on Day 8 of cycles 1,
2, and 3 were similar to the concentrations on Day 4,
ranging between 6.740 ng/mL and 6.890 ng/mL; median
YM155 concentrations in samples collected on Day 8 after
the end of YM155 infusion were lower, ranging between
3.895 ng/mL and 4.535 ng/mL. The median concentration
of two measured metabolites was below the detection
limit at all time points.
Biomarker analysis
Markers of apoptosis
Apoptosis was measured for 57 patients (89.1%; 9 time
points per patient) by detection of a tumor-specific neo-
epitope of cytokeratin 18 (M30) created during apoptotic
cleavage. A statistically significant increase in apoptosis
from baseline was observed on Day 4 of cycles 1–3
(P = 0.003, 0.008, and 0.039, respectively). There was no
significant change from baseline to Day 8 of cycles 1, 2,
or 3; the Day 8 values also appeared to normalize close to
baseline. Best overall clinical response did not have any
statistical correlation with increase in M30.
Markers of resistance
Fifty patients (78.1%) provided archival tumor specimens
for marker analysis. Of the eight patients with partial
response (PR), only six patients provided tumor speci-
mens for evaluation; an ad-hoc logistic regression analysis
found none of the biomarkers was correlated with
response. Forty-five patients (70.3%) who provided tumor
samples were tested for survivin staining; however, only a
small number (n = 4) had high survivin expression levels,
preventing meaningful interpretation of the association
between survivin levels and disease progression.
Efficacy
All efficacy analyses include all 64 enrolled patients. Data
presented are from Independent Review Committee (IRC)
assessment, unless otherwise specified. The median PFS
was 4.2 (95% CI, 2.7–5.6) months (Figure 2). Six-month
Table 2. Adverse events occurring in ≥10% of patients.
Adverse event, n (%)
Grade
1/2
Grade
3/4 All grades
Fatigue 50 (78.1) 5 (7.8) 55 (85.9)
Nausea 40 (62.5) 1 (1.6) 41 (64.1)
Decreased appetite 39 (60.9) 1 (1.6) 40 (62.5)
Neutropenia 2 (3.1) 38 (59.4) 40 (62.5)
Alopecia 37 (57.8) 0 37 (57.8)
Diarrhea 30 (46.9) 4 (6.3) 34 (53.1)
Mucositis 18 (28.1) 6 (9.4) 24 (37.5)
Pyrexia 20 (31.3) 2 (3.1) 22 (34.4)
Rash 19 (29.7) 1 (1.6) 20 (31.3)
Dysgeusia 20 (31.3) 0 20 (31.3)
Constipation 19 (29.7) 0 19 (29.7)
Leukopenia 1 (1.6) 18 (28.1) 19 (29.7)
Decreased neutrophil count 3 (4.7) 16 (25.0) 19 (29.7)
Dyspnea 17 (26.6) 1 (1.6) 18 (28.1)
Vomiting 17 (26.6) 1 (1.6) 18 (28.1)
Anemia 11 (17.2) 6 (9.4) 17 (26.6)
Headache 15 (23.4) 0 15 (23.4)
Peripheral edema 15 (23.4) 0 15 (23.4)
Arthralgia 15 (23.4) 0 15 (23.4)
Hypokalemia 11 (17.2) 3 (4.7) 14 (21.9)
Peripheral neuropathy 14 (21.9) 0 14 (21.9)
Back pain 12 (18.8) 2 (3.1) 14 (21.9)
Pain 12 (18.8) 1 (1.6) 13 (20.3)
Insomnia 12 (18.8) 0 12 (18.8)
Decreased white blood cell count 2 (3.1) 10 (15.6) 12 (18.8)
Febrile neutropenia 1 (1.6) 11 (17.2) 12 (18.8)
Hyponatremia 3 (4.7) 8 (12.5) 11 (17.2)
Stomatitis 10 (15.6) 1 (1.6) 11 (17.2)
Dehydration 7 (10.9) 4 (6.3) 11 (17.2)
Myalgia 10 (15.6) 0 10 (15.6)
Dizziness 10 (15.6) 0 10 (15.6)
Flushing 10 (15.6) 0 10 (15.6)
Hypomagnesemia 10 (15.6) 0 10 (15.6)
Cough 10 (15.6) 0 10 (15.6)
Hyperglycemia 7 (10.9) 2 (3.1) 9 (14.1)
Muscular weakness 9 (14.1) 0 9 (14.1)
Pain in extremity 9 (14.1) 0 9 (14.1)
Abdominal pain 7 (10.9) 1 (1.6) 8 (12.5)
Asthenia 7 (10.9) 1 (1.6) 8 (12.5)
Dry skin 8 (12.5) 0 8 (12.5)
Hypophosphatemia 3 (4.7) 5 (7.8) 8 (12.5)
Edema 8 (12.5) 0 8 (12.5)
Pruritus 8 (12.5) 0 8 (12.5)
Weight decreased 7 (10.9) 1 (1.6) 8 (12.5)
Anxiety 7 (10.9) 0 7 (10.9)
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PFS rate per independent assessment was 34.8% (95% CI,
21.3–48.6%); per Investigator’s assessment, 6-month PFS
was 31.3% (95% CI, 19.5–43.9%). The median OS was
14.9 (95% CI, 8.8–24.3) months, and the estimated prob-
ability of 1-year survival was 56.3% (Figure 3).
The ORR was 12.5% (n = 8), with no complete
responses (CRs) and eight patients (12.5%) with PR. The
stable disease (SD) rate at first follow-up scan (i.e.,
37 days) was 51.6% (n = 33), leading to a CBR
(CR + PR + SD) of 64.1% (n = 41).
Median treatment duration was 70.5 days (Figure 4).
For the eight patients with PR, the median duration of
response was 114 days; median duration on-study for
patients having SD at first evaluation was 151 days. More
patients experienced tumor diameter increase (n = 33;
51.6%) than decrease (n = 26; 40.6%), and the sum of
tumor diameters decreased ≥30% in 12 patients (18.8%;
Figure 5).
Discussion
YM155 is a small molecule survivin suppressant that has
been evaluated for several solid tumors and lymphomas.
Lewis et al. [8] first evaluated this agent in a phase 2 trial
in 34 patients with metastatic melanoma, and showed that
the drug was well tolerated as monotherapy. However, as a
single agent, YM155 resulted in only 1 PR in the patients
treated [8]. Docetaxel has also demonstrated low response
rates as a single agent for treating patients with melanoma
[15]. When considering only those patients who had main-
tained response or stable disease for 84 days, the CBR was
39.1% (CR, 0%; PR, 12.5% [n = 8]; SD, 26.6% [n = 17];
insufficient assessments, 23.4% [n = 15]).
In our study, we hypothesized that the combination of
docetaxel and YM155 would enhance the efficacy of the
individual agents, as was demonstrated in preclinical
studies [3]. This study, with an ORR of 12.5%, demon-
strated higher response rates with YM155 plus docetaxel
than YM155 alone [8], but not docetaxel alone [15].
Although, isolated patients demonstrated significant and
prolonged responses.
No increased toxicity was expected or observed due to
the combination of the two drugs. The majority of
patients experienced Grade 3 or 4 toxicity; however, many
of the toxicities can be attributed to the anticipated effects
of docetaxel (e.g., fatigue, neutropenia, febrile neutrope-
nia, neuropathy, mucositis). Renal failure, which had been
seen in previous studies of YM155 [8], was not seen in
this study. Most events were manageable with supportive
care alone and resolved to baseline with drug interrup-
tions or reductions.
Steady-state plasma concentrations of YM155 in this
study were similar to previous monotherapy studies [17],
suggesting unaltered pharmacokinetics of YM155 when
administered in combination with docetaxel. The high
variability observed in the plasma concentrations of
YM155 was caused by outliers in the data, which could
be caused by cross-contamination of blood samples with
the infusion line at the time of collection.
For tumor-based IHC evaluations of resistance and
mechanistic markers, no correlation was made between
marker positivity and clinical outcomes for patients who
had a best overall response of PR in this study. Other ret-
rospective analyses of patients with melanoma have found
that survivin upregulation was correlated with decreased
survival rate, increased relapse, and chemoresistance [5,
18]. No correlation could be made between survivin
expression levels and disease progression in this study
because of the small number of samples evaluated.
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intervals for progression-free survival per IRC, full analysis set.
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YM155 with docetaxel was not associated with any
unexpected tolerability concerns. The point estimate for
the predetermined primary efficacy endpoint and 95%
CI was achieved per IRC (i.e., 6-month PFS rate
lower bound ≥20%); however, the lower bound of the
95% CI for the Investigator’s assessment was below this
cutoff. These data, combined with the low overall
response rate, do not support further study of YM155
combined with docetaxel in patients with metastatic
melanoma.
Since completion of this study, the role of targeted
therapy in melanoma has rapidly expanded as many new
agents have been approved. Early studies with dabrafenib
and trametinib [19], pembrolizumab [20], and nivolumab
and ipilimumab [21] have demonstrated notable response
rates and durability of benefit. As such, the current com-
bination of YM155 with docetaxel will not be studied
further in metastatic melanoma.
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Figure 4. Duration of best response to YM155 by patient.
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